Legendary Biotech Pioneer Fires a Shot Across Healthcare Industry's Bottom Line
Alexis Borisy, one of the biopharmaceutical industry's most successful entrepreneurs, recently raised $200 million to launch a new company called EQRx. While the amount raised isn't unusual, the mission driving EQRx has raised eyebrows: Bring down exorbitant drug prices.
Another Borisy-founded company called Blueprint Medicines (NASDAQ: BPMC) recently launched its first cancer drug, Ayavakit, with an eye-popping $32,000 list price for a 30-day supply. In stark contrast, EQRx will develop new therapies with the intention of selling them at generic drug prices.
Image source: Getty Images.
Source Fool.com
